Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UDP glucuronosyltransferase family 2 member B26, pseudogene (UGT2B26P), is classified as a pseudogene in the human genome. Pseudogenes are genomic sequences similar to known genes but are non-functional due to mutations or incomplete coding potential. UGT2B26P is annotated as a related sequence to the UGT2B family, which consists of enzymes responsible for glucuronidation reactions in detoxification and metabolism. However, UGT2B26P itself does not produce a functional protein and therefore has no direct role in metabolic processes, drug action, or disease pathogenesis[5]. There is no evidence that UGT2B26P acts as a receptor, enzyme, transporter, or other major drug target class[5]. As a pseudogene, it lacks known interacting drugs, therapeutic relevance, or established biomarker status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UDP glucuronosyltransferase family 2 member B26, pseudogene (UGT2B26P).